A Phase 2 study has compared a combination of ficlatuzumab and gefitinib to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer.
Gilead Sciences Inc. announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.
Quotient Clinical has received approval of the final patent for its Enterion technology. This completes a portfolio of eight granted patents across North America and Europe.
Shire plc announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse in adults with binge eating disorder.
Quark Pharmaceuticals Inc. it has amended an existing exclusive licensing agreement with Pfizer in order to perform a Phase 2a clinical trial of PF-655 on patients with open-angle glaucoma.
A JMP Securities analyst has upgraded Idenix Pharmaceuticals Inc. stock after Idenix reported new data on its experimental hepatitis C drugs.
The Food and Drug Administration approved a new impotence drug, Vivus Inc.'s Stendra. Vivus is talking to potential marketing partners, or it may sell the drug to another company.
Repligen Corporation announced positive results from a Phase 1 study of RG3039, a drug candidate for the potential treatment of spinal muscular atrophy.
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved Votrient for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy.
Genzyme has reported data from a Phase 3 trial that showed accumulation of disability was significantly slower in multiple sclerosis patients who were treated with alemtuzumab versus Rebif.
SMT C1100, an experimental treatment for Duchenne muscular dystrophy, has received approval from regulatory agencies in the United Kingdom to move from laboratory to human testing.
MicroDose Therapeutx, Inc. has concluded the second of two Phase 1 studies with its inhaled antiviral fusion inhibitor, MDT-637, for the treatment of RSV infection.
Indiana University Health and the Indiana University School of Medicine will invest $150 million in a new research collaboration that will enhance the institutions’ capabilities in fundamental scientific investigation, translational research, and clinical trials.
Keryx Biopharmaceuticals said its kidney disease drug Zerenex, a treatment for high phosphate levels in dialysis patients, met its goal in a late-stage clinical trial.
Synairgen plc has announced positive data from its Phase 2 clinical trial to assess SNG001's ability to protect asthmatics from respiratory virus infections that can spread to the lung.
Abbott announced data from an interferon-free, Phase 2 study of Abbott's direct-acting antiviral medicines for hepatitis C that showed over 90% of patients new to HCV treatment achieved SVR12.
Stemline Therapeutics Inc. has announced study results of two clinical trials of direct injection synthetic peptide vaccine, now being developed as SL-701, in both adults and children with advanced brain cancer.
Two drugmakers said that a combination of experimental oral treatments for hepatitis C cured almost all patients in a midstage clinical trial.
Swiss pharmaceutical company Novartis AG says it has halted clinical trials for alisporivir, a new drug to treat hepatitis, after one patient died.
Depomed, Inc. announced that it has completed a Type B pre-NDA meeting with the United States Food and Drug Administration regarding the results of three Phase 3 clinical trials of Serada.
Abbott announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel.
An unusual clinical trial is seeking to determine whether a drug approved for patients with advanced prostate cancer might be safer and just as effective if taken at a much lower dose with food instead of at the full dose on an empty stomach.
The United States Food and Drug Administration has granted Pluristem Therapeutics Inc. clearance to start a Phase 2 clinical trial using the PLX-PAD cell product candidate for the treatment of intermittent claudication.
PROLOR Biotech Inc. reported positive preclinical results from an animal study of its long-acting obesity/type 2 diabetes drug candidate MOD-6030.